| Title: | Clinical case study meets population cohort: identification of a BRCA1 pathogenic founder variant in Orcadians |
| Journal: | European Journal of Human Genetics |
| Published: | 16 Mar 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/36927983/ |
| DOI: | https://doi.org/10.1038/s41431-023-01297-w |
| URL: | https://www.nature.com/articles/s41431-023-01297-w.pdf |
| Citations: | 3 (3 in last 2 years) as of 8 Aug 2024 |
Publication 7903
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
We multiply ascertained the BRCA1 pathogenic missense variant c.5207T > C; p.Val1736Ala (V1736A) in clinical investigation of breast and ovarian cancer families from Orkney in the Northern Isles of Scotland, UK. We sought to investigate the frequency and clinical relevance of this variant in those of Orcadian ancestry as an exemplar of the value of population cohorts in clinical care, especially in isolated populations. Oral history and birth, marriage and death registrations indicated genealogical linkage of the clinical cases to ancestors from the Isle of Westray, Orkney. Further clinical cases were identified through targeted testing for V1736A in women of Orcadian ancestry attending National Health Service (NHS) genetic clinics for breast and ovarian cancer family risk assessments. The variant segregates with female breast and ovarian cancer in clinically ascertained cases. Separately, exome sequence data from 2088 volunteer participants with three or more Orcadian grandparents, in the ORCADES research cohort, was interrogated to estimate the population prevalence of V1736A in Orcadians. The effects of the variant were assessed using Electronic Health Record (EHR) linkage. Twenty out of 2088 ORCADES research volunteers (~1%) carry V1736A, with a common haplotype around the variant. This allele frequency is ~480-fold higher than in UK Biobank participants. Cost-effectiveness of population screening for BRCA1 founder pathogenic variants has been demonstrated at a carrier frequency below the ~1% observed here. Thus we suggest that Orcadian women should be offered testing for the BRCA1 V1736A founder pathogenic variant, starting with those with known Westray ancestry.12 Authors
- Shona M. Kerr
- Emma Cowan
- Lucija Klaric
- Christine Bell
- Dawn O'Sullivan
- David Buchanan
- Joseph J. Grzymski
- Cristopher V. van Hout
- Gannie Tzoneva
- Alan R. Shuldiner
- James F. Wilson
- Zosia Miedzybrodzka
1 Application
| Application ID | Title |
|---|---|
| 19655 | Quantitative and population genetics in UK Biobank |
Enabling scientific discoveries that improve human health